Samarium Sm 153 and Stem Cell Transplant Followed By Radiation Therapy Patients With Osteosarcoma

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

11 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-10-31

Study Completion Date

2009-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Radioactive drugs, such as samarium Sm 153 lexidronam pentasodium, may carry radiation directly to tumor cells and not harm normal cells. A peripheral stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy and samarium Sm 153 lexidronam pentasodium. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving samarium Sm 153 lexidronam pentasodium together with a peripheral stem cell transplant and radiation therapy may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving samarium Sm 153 lexidronam pentasodium together with autologous stem cell transplant and radiation therapy works in treating patients with recurrent or refractory, metastatic, or unresectable osteosarcoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Chemotherapy Plus Radiation Therapy and Biological Therapy in Treating Patients With Hematologic Cancer

NCT00002553

Leukemia Lymphoma

COMPLETED PHASE2

Gemtuzumab Ozogamicin, Fludarabine, and Total-body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT00008151

Leukemia Myelodysplastic Syndromes

COMPLETED PHASE2

A Dose Finding Study of CycloSam® Combined With External Beam Radiotherapy

NCT03612466

Osteosarcoma Bone Metastases

WITHDRAWN PHASE1

Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma

NCT01886105

Metastatic Osteosarcoma

TERMINATED PHASE2

High-Dose Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia in Remission

NCT00002567

Bone Marrow Ablation Leukemia

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

Primary

* Determine the clinical response in patients with recurrent or refractory, metastatic, or unresectable osteosarcoma treated with high-dose samarium Sm 153 lexidronam pentasodium (\^153Sm-EDTMP) and autologous peripheral blood stem cell transplantation followed by external-beam radiotherapy.
* Correlate the amount of radiation delivered to a tumor with low-dose \^153Sm-EDTMP with that of high-dose \^153Sm-EDTMP in patients treated with this regimen.

Secondary

* Determine the overall and progression-free survival of patients treated with this regimen.
* Determine the toxicity of this regimen in these patients.
* Determine the long-term effects of this regimen in these patients.
* Determine the predictive value of fludeoxyglucose F 18 positron emission tomography (FDG-PET), diffusion-weighted MRI, and magnetic resonance spectroscopy for evaluation of treatment response in patients treated with this regimen.

OUTLINE: Patients are stratified according to resectability of the primary tumor (recurrent, refractory, or very high-risk disease vs unresectable primary tumor).

* Mobilization and collection of autologous peripheral blood stem cells (PBSCs)\* : Patients receive ifosfamide IV daily for 5 days followed by filgrastim (G-CSF) subcutaneously daily. Patients then undergo leukapheresis for collection of autologous PBSCs until ≥ 2 x 10\^6 CD34 (cluster of differentiation 34)-positive cells/kg are collected.

NOTE: \*Patients who have undergone PBSC collection before study entry proceed to high-dose samarium Sm 153 lexidronam pentasodium (153Sm-EDTMP) infusion without mobilization and collection of autologous PBSCs.

* 153Sm-EDTMP infusion: Patients receive a trace dose of \^153Sm-EDTMP\*\* IV over 1-2 minutes and undergo bone scan 4, 24, and 48-72 hours later. Six weeks later, patients receive high-dose \^153Sm-EDTMP IV over 1-2 minutes and undergo repeat bone scans 4, 24, and 48-72 hours later.

NOTE: \*\*Patients may receive the trace dose on protocol JHOC (Johns Hopkins Oncology Center)-J0094.

* Autologous peripheral blood stem cell transplantation (PBSCT): Between 12-14 days after administration of high-dose \^153Sm-EDTMP, patients undergo autologous PBSCT. Beginning 2 days later, patients receive G-CSF IV daily.
* External-beam radiotherapy: Patients then undergo external-beam radiotherapy to the sites of bulky disease.
* Surgery: Some patients may also undergo surgical resection of residual disease. After completion of study treatment, patients are followed periodically for up to 3 years.

PROJECTED ACCRUAL: A total of 54 patients will be accrued for this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Samarium-153

Cytoxan+Ifosfamide, Filgrastim pre samarium.'Sm-EDTMP (low dose). once counts recover, Sm-EDTMP (high dose) given. Peripheral blood stem cell transplantation is done 14 days later.

Group Type EXPERIMENTAL

filgrastim

Intervention Type BIOLOGICAL

Filgrastim will be administered post post chemotherapy until target WBC (white blood cell) count is achieved.

ifosfamide

Intervention Type DRUG

Ifosfamide administered IV.

peripheral blood stem cell transplantation

Intervention Type PROCEDURE

Peripheral blood stem cell transplantation is done 14 days after 2nd dose of Samarium is delivered

Sm-EDTMP (low dose)

Intervention Type RADIATION

Sm-EDTMP (low dose) administered after autologous stem cell collection

sm-EDTMP (higher dose)

Intervention Type RADIATION

Upon blood cell count recovery from Sm-EDTMP (low dose), Sm-EDTMP (higher dose) is administered followed in 14 days by peripheral blood stem cell transplantation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

filgrastim

Filgrastim will be administered post post chemotherapy until target WBC (white blood cell) count is achieved.

Intervention Type BIOLOGICAL

ifosfamide

Ifosfamide administered IV.

Intervention Type DRUG

peripheral blood stem cell transplantation

Peripheral blood stem cell transplantation is done 14 days after 2nd dose of Samarium is delivered

Intervention Type PROCEDURE

Sm-EDTMP (low dose)

Sm-EDTMP (low dose) administered after autologous stem cell collection

Intervention Type RADIATION

sm-EDTMP (higher dose)

Upon blood cell count recovery from Sm-EDTMP (low dose), Sm-EDTMP (higher dose) is administered followed in 14 days by peripheral blood stem cell transplantation.

Intervention Type RADIATION

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Neupogen Ifex

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of osteosarcoma

* High-risk disease, meeting 1 of the following criteria:

* Recurrent disease
* Refractory to conventional therapy
* Newly diagnosed metastatic disease with ≥ 4 pulmonary nodules or multiple bone lesions
* Unresectable primary tumor
* Prior intralesional resection allowed
* Measurable disease by technetium Tc 99m diphosphonate bone scan
* Refractory to all standard therapies or highly unlikely to respond to conventional treatment
* Performance status Karnofsky 60-100%
* Life expectancy more than 8 weeks
* Absolute neutrophil count \> 500/mm\^3
* Platelet count \> 50,000/mm\^3
* Creatinine clearance \> 70 mL/min OR \* Radioisotope glomerular filtration rate normal
* Recovered from prior chemotherapy

Exclusion

* Pregnant or nursing
* Positive pregnancy test for females of childbearing potential
* Fertile patients do not agree to use effective contraception
* Prior radiotherapy to the site of currently active disease
* Concurrent enrollment on protocol JHOC-J0094 allowed

Minimum Eligible Age

13 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No